Mili Kit
Product Images NDC 65862-776

6 FDA label images from Aurobindo Pharma Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Mili (NDC 65862-776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Norgestimate Fig1)

Figure 1 (Norgestimate Fig1)
An instructional diagram for the Mili kit containing norgestimate and ethinyl estradiol tablets. It shows a hand placing a day label strip above a four-week pill pack organized into four rows labeled Week 1 to Week 4. Each row has circular tablet positions, with Week 4 tablets shaded green and the rest shaded dark blue. The image instructs to pick the correct day label and place it on the pack to track daily usage.*
FDA Label Image

Chemical Structure (Norgestimate Str)

Chemical Structure (Norgestimate Str)
Chemical structure diagram showing the molecular structures of norgestimate and ethinyl estradiol, the active ingredients in the prescription drug kit Mili. The structures depict steroidal frameworks with labeled groups such as methyl, hydroxyl, and ethynyl substituents.*
FDA Label Image

Figure 2 (Norgestimate Fig2)

Figure 2 (Norgestimate Fig2)
Mili kit blister pack for oral tablets containing norgestimate and ethinyl estradiol. The pack shows 28 round tablets organized in four weeks, with three weeks of dark blue tablets and one week of green tablets. Days of the week are labeled Sunday through Saturday along the top, guiding daily dosing.*
FDA Label Image

Figure 3 (Norgestimate Fig3)

Figure 3 (Norgestimate Fig3)
A forest plot chart showing effect estimates (odds ratios/relative risks) from various studies on contraceptive use. The studies include the NICHD Women's Contraceptive Study, French E3N cohort Study, Shangai Women's Health Study, The Nurses' Health Study II, Oxford Family Planning Association Study, and Danish Sex Hormone Register Study. Each study has a corresponding point estimate with confidence intervals plotted along an x-axis ranging approximately from -1.5 to 2.*
FDA Label Image

Figure 4 (Norgestimate Fig4)

Figure 4 (Norgestimate Fig4)
Diagram illustrating pregnancy rates per 100 women in one year, organized by contraceptive methods. It ranges from fewer than 1 pregnancy with implants, injections, intrauterine devices, and sterilization, to higher pregnancy rates with birth control pills, skin patches, and vaginal rings. Condoms and diaphragms show intermediate rates, while methods like no sex during fertile days, spermicides, and withdrawal have higher pregnancy numbers. 'No birth control' results in the most pregnancies.*
FDA Label Image

Package Label-principal Display Panel (0.250 mg/0.035 mg Blister Carton Label)

Package Label-principal Display Panel (0.250 mg/0.035 mg Blister Carton Label)
An instructional diagram showing how to use a Mili (norgestimate and ethinyl estradiol) 28-day oral contraceptive kit. It depicts a hand peeling a correct-day label (Monday through Sunday) to place over the pill pack's day labels. The pill pack is divided into four weeks, with the first three weeks containing dark blue tablets and the fourth week green tablets, indicating the sequence of daily dosage.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.